# Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct04649060/  
OnCo record `nct04649060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Melphalan flufenamide, Dexamethasone and Daratumumab in Multiple myeloma, run by Oncopeptides AB, recorded as terminated on the registry.

## Summary

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT04649060 by Oncopeptides AB, with 54 participants recorded, started 2020-12-21 and due to reach its primary completion in 2022-02-07. Interventions recorded: Melflufen, Dexamethasone, Daratumumab. Conditions recorded: Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma.

Linked to the drug Melphalan flufenamide because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04649060
- Phase: 3
- Setting: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
- Sponsor: Oncopeptides AB
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT04649060: https://clinicaltrials.gov/study/NCT04649060

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Melphalan flufenamide](https://onco.cc/drugs/melflufen/)
- companies: [Oncopeptides](https://onco.cc/companies/oncopeptides/)

---
JSON: https://onco.cc/api/v1/entities/nct04649060.json